Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Other hematologic neoplasm 1

Conditions

Mesothelioma, Malignant 1Mesothelioma 1

Interventions

Cisplatin 4Docetaxel 3pembrolizumab 2Nivolumab 2Etoposide 2Carboplatin 2osimertinib 1icotinib 1famitinib 1durvalumab 1decitabine and cedazuridine drug combination 1dabrafenib 1cemiplimab 1alirocumab 1aldesleukin 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiosurgery 1Radionuclide Imaging 1Radiation 1Prednisone 1Positron-Emission Tomography 1Platinum 1Pemetrexed 1Panitumumab 1Paclitaxel 1Monatide (IMS 3015) 1Methods 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × decitabine and cedazuridine drug combination × Thoracic × Clear all
NCT05960773 2026-05-04

Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

National Institutes of Health Clinical Center (CC)

Phase 2 Suspended
9 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡